BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ceplene histamine dihydrochloride regulatory update

EpiCept said the Israeli Ministry of Health approved Ceplene histamine dihydrochloride for the remission maintenance and prevention of relapse in patients with acute myelogenous leukemia (AML). The company plans to...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >